Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
The objective of this study is to determine if comprehensive lifestyle changes may slow, stop, or reverse the progression of early-stage Alzheimer's disease.
Description: The ADAS-Cog test is one of the most frequently used tests to measure cognition in clinical trials. Patients obtain scores of 0 to 70; higher scores indicate poorer performance.
Measure: Change from Baseline in Alzheimer Disease Assessment Scale cognitive section (ADAS-Cog) score Time: At baseline and also after 20 weeks, 40 weeks, and 2 yearsDescription: The CGIC test is often used in clinical trials of cognition. CGIC scores range from 1 (very much improved) through to 7 (very much worse).
Measure: Change from Baseline in Clinical Global Impression of Change (CGIC) score Time: At baseline and also after 20 weeks, 40 weeks, and 2 yearsDescription: The CDR-SOB is a commonly used dementia staging instrument. The CDR-SOB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18 (lower is better).
Measure: Change from Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score Time: At baseline and also after 20 weeks, 40 weeks, and 2 yearsDescription: This test measures the type and relative preponderance of gut organisms at Rob Knight's lab at UCSD. To assess whether this intervention is associated with a systematic signal in the gut microbiome, he will use 16S rRNA amplicon sequencing, metagenomic sequencing, and untargeted mass spectrometry to analyze stool samples of these study participants. This will provide the relative proportion of organisms in the microbiome of these patients at each time interval.
Measure: Changes from baseline in the microbiome Time: At baseline and also after 20 weeks, 40 weeks, and 2 yearsDescription: The leukocyte telomere length assay from PBMCs will be performed in the laboratory of Dr. Elizabeth Blackburn at UCSF using the quantitative polymerase chain reaction method to measure telomere length relative to standard reference DNA, expressed as telomere to single-copy gene ratio (T/S).
Measure: Changes from baseline in telomere length Time: At baseline and also after 20 weeks, 40 weeks, and 2 yearsDescription: These are measures of inflammation (C-reactive protein in mg/L), lipids (total cholesterol, LDL-cholesterol, triglycerides in mg/dl), blood pressure (mm Hg), and weight (pounds).
Measure: Changes from baseline in biomarkers Time: At baseline and also after 20 weeks, 40 weeks, and 2 yearsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports